Ardelyx, Inc. (ARDX)
3.34
-0.04
(-1.18%)
USD |
NASDAQ |
Oct 02, 16:00
3.335
0.00 (0.00%)
After-Hours: 20:00
Ardelyx Enterprise Value : 806.51M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 806.51M |
| October 01, 2026 | 816.48M |
| September 30, 2026 | 826.44M |
| September 29, 2026 | 818.97M |
| September 28, 2026 | 823.95M |
| September 25, 2026 | 826.44M |
| September 24, 2026 | 833.92M |
| September 23, 2026 | 841.39M |
| September 22, 2026 | 876.27M |
| September 21, 2026 | 846.37M |
| September 18, 2026 | 826.44M |
| September 17, 2026 | 816.48M |
| September 16, 2026 | 818.97M |
| September 15, 2026 | 821.46M |
| September 14, 2026 | 851.36M |
| September 11, 2026 | 866.31M |
| September 10, 2026 | 876.27M |
| September 09, 2026 | 921.12M |
| September 08, 2026 | 913.64M |
| September 04, 2026 | 916.14M |
| September 03, 2026 | 898.70M |
| September 02, 2026 | 921.12M |
| September 01, 2026 | 911.15M |
| August 31, 2026 | 916.14M |
| August 28, 2026 | 923.61M |
| Date | Value |
|---|---|
| August 27, 2026 | 926.10M |
| August 26, 2026 | 928.59M |
| August 25, 2026 | 916.14M |
| August 24, 2026 | 906.17M |
| August 21, 2026 | 943.54M |
| August 20, 2026 | 946.03M |
| August 19, 2026 | 978.42M |
| August 18, 2026 | 951.02M |
| August 17, 2026 | 985.90M |
| August 14, 2026 | 985.90M |
| August 13, 2026 | 948.53M |
| August 12, 2026 | 963.47M |
| August 11, 2026 | 956.00M |
| August 10, 2026 | 970.95M |
| August 07, 2026 | 970.95M |
| August 06, 2026 | 1.188B |
| August 05, 2026 | 1.198B |
| August 04, 2026 | 1.223B |
| August 03, 2026 | 1.215B |
| July 31, 2026 | 1.208B |
| July 30, 2026 | 1.230B |
| July 29, 2026 | 1.220B |
| July 28, 2026 | 1.241B |
| July 27, 2026 | 1.235B |
| July 24, 2026 | 1.228B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Capricor Therapeutics, Inc. | 373.19M |
| REGENXBIO, Inc. | 547.16M |
| Compass Therapeutics, Inc. | -15.96M |
| ARS Pharmaceuticals, Inc. | 357.54M |
| Sionna Therapeutics, Inc. | 18.79M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.72M |
| Revenue (Quarterly) | 120.88M |
| Total Expenses (Quarterly) | 137.60M |
| EPS Diluted (Quarterly) | -0.0674 |
| Gross Profit Margin (Quarterly) | 94.74% |
| Profit Margin (Quarterly) | -13.83% |
| Earnings Yield | -6.77% |
| Normalized Earnings Yield | -6.766 |